Sanofi Drug Shortage Cancels Some U.S. Infusions

Shortage of Pompe disease therapies has lasted over three months, tied to manufacturing issues at a Irish plant.

Updated on Nov. 20, 2026 in Healthcare

Sanofi Drug Shortage Cancels Some U.S. Infusions

Sanofi's Lumizyme and Nexviazyme, used to treat Pompe disease, have been in short supply for more than three months, and some U.S. patients have had infusions canceled. The company attributes the shortage to manufacturing problems at its Waterford, Ireland facility.

Why it matters

The FDA sent Sanofi a warning letter on June 22 stating the company had not addressed the underlying failure to comply with manufacturing requirements, after violations were found at the plant in January. Sanofi has shipped imported product to countries with treatment interruptions while a new manufacturing process approved by the European Medicines Agency and FDA is meant to expand capacity.

Pompe disease affects about 1 in 19,000 babies, and patients typically receive Sanofi's drugs by infusion every two weeks. The number of affected U.S. patients has not been disclosed, and shipping delays could extend interruptions through the end of November.

The players

Sanofi

A French multinational pharmaceutical company that manufactures the Pompe disease therapies Lumizyme and Nexviazyme.

U.S. Food and Drug Administration (FDA)

The federal agency responsible for regulating drug manufacturing and safety in the United States, which issued the warning letter to Sanofi.

European Medicines Agency

The European Union agency responsible for the scientific evaluation of medicines, which approved a new manufacturing process for Sanofi's therapies.

The details

Sanofi's latest supply update was issued on October 16. The FDA inspected the Waterford plant in January and found violations involving two unrelated drugs, and the company has shipped imported product to countries experiencing treatment interruptions.

Timeline

  1. January: FDA inspected the Waterford, Ireland plant and found violations.

  2. June 22: FDA sent Sanofi a warning letter on unresolved manufacturing failures.

  3. October 16: Sanofi issued its latest supply update.

  4. Through the end of November: Shipping delays could interrupt infusions for some U.S. patients.

Healthcare Supply Context

The Sanofi shortage follows the FDA's escalation pattern of issuing formal warning letters when inspection violations at biologic manufacturing plants are not corrected. Its reliance on a single Waterford, Ireland facility for Pompe therapies illustrates how concentrated production can leave U.S. patients exposed when one site falls out of compliance.

Patients receiving Pompe disease infusions every two weeks may face canceled or delayed treatments while the shortage continues. Families should consult their treating physicians about alternative scheduling or supply options if an infusion is postponed.

The takeaway

Patients who rely on enzyme replacement infusions should plan ahead with their care teams, since manufacturing problems at a single plant can interrupt treatment for months. Keeping a clear record of scheduled infusions can help patients act quickly if a delay occurs.

What happens next

Sanofi has projected that shipping delays could interrupt infusions for some U.S. patients through the end of November, and the timing of any resumption of normal supply has not been announced.

Further reading

For more on how supply problems reach the people who depend on these drugs, see Healthcare coverage across the site.

Source note: This article includes information reported by Becker's Hospital Review | Healthcare News & Analysis.